1. What Is the mRNA Therapeutics Non-Vaccine Market?
The mRNA Therapeutics Non-Vaccine Market covers messenger RNA-based medicines designed to produce therapeutic proteins in the body for the treatment of genetic diseases, cancer, and other conditions, supplied to patients through hospital and infusion-centre administration. Clinicians use non-vaccine mRNA therapeutics to instruct cells to produce proteins that are absent, deficient, or therapeutically beneficial, without requiring integration into the cell's genome. The market serves rare genetic diseases where the encoded protein addresses an enzyme deficiency or structural defect, personalised cancer neoantigen vaccines, and emerging cardiovascular and metabolic applications. It includes the mRNA molecules, lipid nanoparticle delivery systems, and the formulation, with demand driven by the platform technology demonstrated in COVID-19 vaccines and the pipeline of non-vaccine applications it is accelerating.
2. mRNA Therapeutics Non-Vaccine Market Size & Forecast
3. Emerging Technologies
- Personalised neoantigen mRNA vaccines encoding patient-specific tumour mutations for combination with checkpoint inhibitor immunotherapy.
- mRNA enzyme replacement therapy encoding missing metabolic enzymes for monthly dosing in rare metabolic diseases.
- Lipid nanoparticle delivery systems protecting mRNA from degradation and enabling cellular uptake.
- Cardiac and regenerative mRNA therapies encoding growth factors for myocardial repair.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Retinal Gene Therapy Market.
4. Key Market Opportunity
The largest near-term opportunity in the mRNA Therapeutics Non-Vaccine market lies in oncology centres participating in personalised mRNA neoantigen vaccine trials alongside checkpoint inhibitor therapy. A second, faster-growing opportunity lies in rare disease specialists adopting mRNA enzyme replacement when approved for metabolic deficiency conditions. As adoption broadens, the addressable opportunity is expanding from early deployments toward wider commercial use, with Europe positioned for the most rapid growth through 2034.
5. Top Companies in the mRNA Therapeutics Non-Vaccine Market
The following organisations hold leading positions in the mRNA Therapeutics Non-Vaccine Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Moderna
- BioNTech
- Arctus Biotherapeutics
- CureVac
- Translate Bio (Sanofi)
- Ethris
- Providence Therapeutics
- Larimar Therapeutics
- MiNA Therapeutics
- AstraZeneca (mRNA programme)
6. Market Segmentation
The mRNA Therapeutics Non-Vaccine Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Application | Oncology and Personalised Cancer Vaccine Rare Genetic Disease Cardiovascular Respiratory |
| By Disease Area | Enzyme Deficiency Cancer Neoantigen Protein Replacement |
| By Administration | Intravenous Intramuscular Intratumoural |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the mRNA Therapeutics Non-Vaccine Market trajectory over the forecast period:
The COVID-19 mRNA Vaccine Platforms from Moderna and BioNTech Demonstrated Scaled Lipid Nanoparticle Manufacturing.The COVID-19 mRNA vaccine platforms from Moderna and BioNTech demonstrated scaled lipid nanoparticle manufacturing and established global regulatory confidence in mRNA medicine that dramatically accelerated the pipeline for non-vaccine applications. The manufacturing experience, lipid nanoparticle formulation advances, and regulatory precedent from vaccine programmes are being applied to therapeutic programmes. Moderna's cancer vaccine programme in melanoma, combining mRNA personalised neoantigen vaccine with pembrolizumab, has shown promising relapse-free survival data that advanced it to Phase 3 trials. This oncology programme represents the most advanced non-vaccine mRNA therapeutic candidate from the companies that built COVID vaccine platforms.
Rare Genetic Disease Is the Second Major Application.Rare genetic disease is the second major application, as mRNA can instruct liver cells to produce enzymes that are deficient in metabolic disorders including propionic acidaemia and methylmalonic acidaemia. Moderna and Arctus Biotherapeutics are advancing mRNA programmes for these conditions. The enzyme replacement approach using mRNA avoids the manufacturing complexity of protein-based enzyme replacement while potentially providing repeated dosing without immunogenicity accumulation. This rare disease application addresses conditions where no or inadequate treatments exist.
Personalised Cancer Vaccines Represent a New Therapeutic Category.Personalised cancer vaccines represent a new therapeutic category, as sequencing a patient's tumour and manufacturing a personalised neoantigen mRNA vaccine against that patient's specific mutations is now technically feasible. The clinical activity data from Moderna's mRNA-4157 programme is the most watched non-vaccine mRNA result. This personalised manufacturing model represents an innovation in cancer treatment.
For related market intelligence, see the T Cell Therapy Market.
8. Segmental Analysis
By application, the oncology and personalised cancer vaccine segment dominated the mRNA Therapeutics Non-Vaccine Market in 2025, as cancer neoantigen vaccine development represents the most clinically advanced and highest-profile non-vaccine mRNA therapeutic category.
By application, the rare genetic disease segment is projected to register the highest CAGR in the mRNA Therapeutics Non-Vaccine Market through 2034, as metabolic enzyme replacement mRNA approaches approval, driving the fastest-growing application category within the market.
9. Regional Analysis
Regional demand patterns across the mRNA Therapeutics Non-Vaccine Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the mRNA Therapeutics Non-Vaccine Market in 2025, accounting for the largest share of revenue. Moreover, the United States hosts the most advanced clinical programmes including Moderna's personalised cancer vaccine Phase 3 and multiple rare disease mRNA studies. In addition, FDA engagement with mRNA platform precedent from vaccines accelerates regulatory review. The concentration of mRNA platform investment and clinical development activity at Moderna and biotech partners anchors revenue leadership.
Highest CAGR Region
Europe is projected to register the highest CAGR in the mRNA Therapeutics Non-Vaccine Market through 2034. The primary driver is BioNTech's European base and leadership in personalised cancer vaccine development, alongside CureVac and Ethris advancing specialised mRNA programmes. Moreover, European academic-industry collaboration in mRNA is deep and sustained by research funding. The combination of these demand drivers and an expanding base positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The mRNA Therapeutics Non-Vaccine Market was valued at USD 4.25 Bn in 2025 and is projected to reach USD 40.86 Bn by 2034, growing at a CAGR of 28.6% over the 2026–2034 forecast period.
The mRNA Therapeutics Non-Vaccine Market is projected to grow at a CAGR of 28.6% from 2026 to 2034.
North America dominated the mRNA Therapeutics Non-Vaccine Market in 2025, accounting for the largest share of revenue.
The leading companies in the mRNA Therapeutics Non-Vaccine Market include Moderna, BioNTech, Arctus Biotherapeutics, CureVac, Translate Bio (Sanofi), Ethris, Providence Therapeutics, Larimar Therapeutics, MiNA Therapeutics, AstraZeneca (mRNA programme).
The covid-19 mrna vaccine platforms from moderna and biontech demonstrated scaled lipid nanoparticle manufacturing.
By application, the oncology and personalised cancer vaccine segment dominated the mRNA Therapeutics Non-Vaccine Market in 2025, as cancer neoantigen vaccine development represents the most clinically advanced and highest-profile non-vaccine mRNA therapeutic category.
How to Order
Choose Your Package
Condensed edition of this study for students, researchers and academic institutions.
- Condensed edition of the full study
- For students, researchers & academic institutions
- Valid student ID or institutional email required
- Educational, non-commercial use only
The competitive landscape, including key market participants, company size, market positioning, and comparative competitive standing.
- 15 in-depth company profiles
- Company overview
- Product and brand portfolio mapped per company
- Revenue for the last 3 FYs with key financial metrics
- Segmental revenue and regional revenue breakdown
- Market presence, key geographies & end-use industries
- Recent developments
- Key capabilities, differentiators & strategic positioning
- SWOT Analysis
- 15-company market share analysis
- 2025 market share by company
- Company revenue in USD
- Competitive quadrant positioning
- Product portfolio comparison
The complete forecast model, including every study table, is provided in clean, formula-ready Excel format across 3 segmentation axes. Select the geographic coverage required for your analysis.
- One country, broken out across 3 segmentation axes
- 2025 base year, 2026–2034 forecast, CAGR per line
- Excel workbook
- Region totals plus every country inside that region
- All axes, all years, CAGR per line
- Cross-country comparison sheet included
- Excel workbook
- Every forecast table in the study
- Global, regional and country views in one workbook
- Segment share and CAGR pivots included
- Excel workbook
The full syndicated study. Every chapter, every region, every country, plus the complete Excel model, methodology and appendix.
- Executive summary, market scope & segmental snapshot
- Market dynamics: drivers, restraints, opportunities, challenges
- Quantitative analysis across 3 segmentation axes
- Regional analysis
- Competitive landscape, market share & company revenue mapping
- Includes the full Global Excel Data Pack
- Complete research methodology, assumptions & appendix
TAM/SAM/SOM sizing, M&A target screening, patent & IP analysis, supply-chain resilience mapping, ESG roadmaps and other bespoke strategic work.
- TAM / SAM / SOM sizing
- M&A target screening
- Patent & IP analysis
- Supply-chain resilience mapping
- ESG roadmaps & other bespoke strategic work
Not sure which package fits? Tell us the decision you are making and an analyst will recommend the smallest package that answers it. Talk to an analyst.
Ordering Process
Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.